Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Bladder Cancer

  Free Subscription


Articles published in J Urol

Retrieve available abstracts of 161 articles:
HTML format



Single Articles


    April 2024
  1. ALLORY Y, Culine S, Krucker C, Fontugne J, et al
    Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.
    J Urol. 2024;211:564-574.
    PubMed     Abstract available


    March 2024
  2. MONTORSI F, Moschini M, Gandaglia G, Briganti A, et al
    Letter: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 +/- Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATL
    J Urol. 2024;211:482-483.
    PubMed    


  3. GILL IS, Desai MM, Cacciamani GE, Khandekar A, et al
    Robotic Radical Cystectomy for Bladder Cancer: The Way Forward.
    J Urol. 2024;211:476-480.
    PubMed    


  4. BOCHNER BH, Kamat AM, Bivalacqua TJ
    Open vs Robotic Cystectomy: Case Closed?
    J Urol. 2024;211:473-475.
    PubMed    


    February 2024
  5. WEISS K, Abimbola O, Mueller D, Basak R, et al
    Feasibility, Acceptability, and Outcomes of a Mobile Health Tool for Radical Cystectomy Recovery.
    J Urol. 2024;211:266-275.
    PubMed     Abstract available


  6. KAY H, Matulewicz RS, Bjurlin MA
    Clearing the Smoke: Underreporting of Smoking Status in Food and Drug Administration-Approved Bladder Cancer Therapeutic Trials.
    J Urol. 2024 Feb 1:101097JU0000000000003853. doi: 10.1097/JU.0000000000003853.
    PubMed    


    January 2024
  7. HOLZBEIERLEIN JM, Bixler BR, Buckley DI, Chang SS, et al
    Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
    J Urol. 2024 Jan 24:101097JU0000000000003846. doi: 10.1097/JU.0000000000003846.
    PubMed     Abstract available


    November 2023
  8. SOOD A, Rudzinski JK, Labbate CV, Hensley PJ, et al
    Long-Term Oncological Outcomes in Patients Diagnosed with Non-Metastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience.
    J Urol. 2023 Nov 3:101097JU0000000000003778. doi: 10.1097/JU.0000000000003778.
    PubMed     Abstract available


    September 2023
  9. PRASAD SM
    Primary Chemoablation for Intermediate-Risk Low-Grade Bladder Cancer: New Paradigm or Added Uncertainty? Letter.
    J Urol. 2023 Sep 28:101097JU0000000000003729. doi: 10.1097/JU.0000000000003729.
    PubMed    


  10. MURTHY PB, Sexton WJ
    Primary Chemoablation for Intermediate-risk Low-grade Bladder Cancer: New Paradigm or Added Uncertainty?
    J Urol. 2023 Sep 27:101097JU0000000000003702. doi: 10.1097/JU.0000000000003702.
    PubMed    


  11. BREE KK, Navai N
    Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 Sep 25:101097JU0000000000003704. doi: 10.1097/JU.0000000000003704.
    PubMed    


  12. BREE K, Navai N
    Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 Sep 25:101097JU0000000000003705. doi: 10.1097/JU.0000000000003705.
    PubMed    


  13. CLEMENTS MB, Beech BB, Atkinson TM, Dalbagni GM, et al
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. Reply.
    J Urol. 2023;210:408.
    PubMed    


  14. WONG N, So WZ, Tiong HY
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. Letter.
    J Urol. 2023;210:407-408.
    PubMed    


    August 2023
  15. PRASAD SM, Huang WC, Shore ND, Hu B, et al
    Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 +/- Transurethral Resection of Bladder Tumor (TURBT) Compared to TURBT Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
    J Urol. 2023 Aug 7:101097JU0000000000003645. doi: 10.1097/JU.0000000000003645.
    PubMed     Abstract available


  16. TAN WS, Contieri R, Buffi NM, Lughezzani G, et al
    International Bladder Cancer Group Intermediate-risk Non-muscle Invasive Bladder Cancer (IBCG IR-NMIBC) Scoring System Predicts Outcomes of Patients on Active Surveillance.
    J Urol. 2023 Aug 3:101097JU0000000000003639. doi: 10.1097/JU.0000000000003639.
    PubMed     Abstract available


    July 2023
  17. JI J, Lai CH, Wang Q, Hu H, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic But Not Therapeutic. Letter.
    J Urol. 2023 Jul 6:101097JU0000000000003613. doi: 10.1097/JU.0000000000003613.
    PubMed    



  18. PD44-11 Neoadjuvant Chemotherapy Increases Urinary and Bowel Anastomotic Failure in PT2-T4 Bladder Cancer Undergoing Radical Cystectomy.
    J Urol. 2023;210:222.
    PubMed    


    June 2023
  19. COLEMAN JA, Clark PE, Bixler BR, Buckley DI, et al
    Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline.
    J Urol. 2023;209:1071-1081.
    PubMed     Abstract available


  20. WANG HH, Zhang TR, Ramakrishnan VM, Valovska MT, et al
    Long-term Urological Outcomes in Pelvic Genitourinary Rhabdomyosarcoma: A 48-Year Single-center Experience.
    J Urol. 2023;209:1202-1209.
    PubMed     Abstract available


    May 2023
  21. BREE KK, Kokorovic A, Westerman ME, Hensley PJ, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 May 22:101097JU0000000000003553. doi: 10.1097/JU.0000000000003553.
    PubMed    


  22. TYSON MD, Morris D, Palou J, Rodriguez O, et al
    Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.
    J Urol. 2023;209:890-900.
    PubMed     Abstract available


  23. GILBERT SM
    Will Patient-reported Outcomes Be the Key to Demonstrating the Value of Robotic Cystectomy? Data Are Accumulating but Clarity Is Not.
    J Urol. 2023;209:833-835.
    PubMed    


  24. GHOREIFI A, Ladi-Seyedian SS, Piatti P, Chew YC, et al
    A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study.
    J Urol. 2023;209:854-862.
    PubMed     Abstract available


  25. KIRK PS, Lotan Y, Zargar H, Fairey AS, et al
    Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort.
    J Urol. 2023;209:882-889.
    PubMed     Abstract available


  26. YIP W, Sjoberg DD, Nogueira LM, Tracey AT, et al
    Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.
    J Urol. 2023;209:863-871.
    PubMed     Abstract available


  27. CLEMENTS MB, Beech BB, Atkinson TM, Dalbagni GM, et al
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial.
    J Urol. 2023;209:901-910.
    PubMed     Abstract available


  28. LABBATE C, Woldu S, Murray K, Rose K, et al
    Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
    J Urol. 2023;209:872-881.
    PubMed     Abstract available


    April 2023
  29. MOSCHINI M, Necchi A, Briganti A, Montorsi F, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Letter.
    J Urol. 2023 Apr 10:101097JU0000000000003455. doi: 10.1097/JU.0000000000003455.
    PubMed    


  30. PENG CK, Sung WW
    Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. Letter.
    J Urol. 2023;209:676-677.
    PubMed    


  31. LOTAN Y, Raman JD, Konety B, Daneshmand S, et al
    Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.
    J Urol. 2023;209:762-772.
    PubMed     Abstract available


    March 2023
  32. STEINBERG RL, O'Donnell MA, Packiam VT
    Non-risk Adapted Sequential Intravesical Gemcitabine and Docetaxel for Non-muscle Invasive Bladder Cancer: The Time is Now.
    J Urol. 2023 Mar 31:101097JU0000000000003438. doi: 10.1097/JU.0000000000003438.
    PubMed    


  33. PENG CK, Sung WW, Chen SL
    Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    J Urol. 2023 Mar 9:101097JU0000000000003407. doi: 10.1097/JU.0000000000003407.
    PubMed    


  34. PRUNTY M, Shoag J
    National Adherence to Guidelines for Antimicrobial Prophylaxis for Patients Undergoing Radical Cystectomy. Reply.
    J Urol. 2023;209:508-509.
    PubMed    


  35. VANDEN BERG RNW, Abern M
    National Adherence to Guidelines for Antimicrobial Prophylaxis for Patients Undergoing Radical Cystectomy. Letter.
    J Urol. 2023;209:508.
    PubMed    


  36. MASTROIANNI R, Ochoa Arvizo MA, Torregiani G, Simone G, et al
    Robot-assisted vs Open Radical Cystectomy: Randomized Controlled Trials Lights and Shadows.
    J Urol. 2023;209:460-461.
    PubMed    


  37. TISSOT G, Xylinas E
    Lymph Node Dissection in Upper Tract Urothelial Cancer: Ready for Prime Time?
    J Urol. 2023;209:462-463.
    PubMed    


  38. PALLAUF M, D'Andrea D, Konig F, Laukhtina E, et al
    Diagnostic Accuracy of Clinical Lymph Node Staging for Upper Tract Urothelial Cancer Patients: A Multicenter, Retrospective, Observational Study.
    J Urol. 2023;209:515-524.
    PubMed     Abstract available


  39. MYERS A, Frank I, Shah PH, Tarrell RF, et al
    Intraoperative Blood Transfusion Is Associated With Increased Risk of Venous Thromboembolism After Radical Cystectomy.
    J Urol. 2023;209:525-531.
    PubMed     Abstract available


    February 2023
  40. CASTANEDA PR, Ahdoot M, Rosser CJ
    Re: Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomyis Prognostic but Not Therapeutic.
    J Urol. 2023 Feb 8:101097JU0000000000003362. doi: 10.1097/JU.0000000000003362.
    PubMed    


  41. PRUNTY M, Rhodes S, Rivero MJ, Callegari M, et al
    National Adherence to Guidelines for Antimicrobial Prophylaxis for Patients Undergoing Radical Cystectomy.
    J Urol. 2023;209:329-336.
    PubMed     Abstract available


  42. HUELSTER HL, Zemp L, Turner K, Gonzalez BD, et al
    Mobile Postoperative Symptom Intervention Tool and Biometric Monitoring After Radical Cystectomy: Pilot Study Evaluating Feasibility, Usability, and Potential Utility.
    J Urol. 2023;209:410-421.
    PubMed     Abstract available


    January 2023
  43. LYON TD, Boorjian SA, Tyson MD
    In-Home Intravesical Therapy: The Future of Non-muscle Invasive Bladder Cancer Care Delivery?. Letter.
    J Urol. 2023 Jan 13:101097JU0000000000003176. doi: 10.1097/JU.0000000000003176.
    PubMed    


    October 2022
  44. LEE HW, Lee HH, Park EY, Park WS, et al
    Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately before Transurethral Resection of Bladder Tumor in Patients with Non-muscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    J Urol. 2022 Oct 12:101097JU0000000000003002. doi: 10.1097/JU.0000000000003002.
    PubMed     Abstract available


  45. BREE KK, Kokorovic A, Westerman ME, Hensley PJ, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic.
    J Urol. 2022 Oct 11:101097JU0000000000003015. doi: 10.1097/JU.0000000000003015.
    PubMed     Abstract available


  46. MATULEWICZ RS, Whiting K, Bochner BH, Ostroff JS, et al
    Knowledge of bladder cancer risk factors among patients diagnosed with non-muscle invasive bladder cancer.
    J Urol. 2022 Oct 4:101097JU0000000000002978. doi: 10.1097/JU.0000000000002978.
    PubMed    


  47. NOGUEIRA LM, Yip W, Assel MJ, Tracey AT, et al
    Survival Impact of Variant Histology Diagnosis in Upper Tract Urothelial Carcinoma.
    J Urol. 2022;208:813-820.
    PubMed     Abstract available


    September 2022
  48. NAZMIFAR M, Williams C, Naser-Tavakolian A, Heard J, et al
    Clinical and Preclinical Therapies for Bladder Cancer Following BCG Failure.
    J Urol. 2022 Sep 6:101097JU0000000000002957. doi: 10.1097/JU.0000000000002957.
    PubMed     Abstract available


  49. PARISSE T, Reines K, Basak R, Mueller D, et al
    Patient and Provider Perception of Transurethral Resection of Bladder Tumor vs. Chemoablation for Non-Muscle Invasive Bladder Cancer Treatment.
    J Urol. 2022 Sep 6:101097JU0000000000002941. doi: 10.1097/JU.0000000000002941.
    PubMed     Abstract available


  50. MEEKS JJ, Sexton WJ, Clark PE
    Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-Guerin.
    J Urol. 2022;208:526-527.
    PubMed    


  51. TERRITO A, Gallioli A, Diana P, Boissier R, et al
    DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical Trial.
    J Urol. 2022;208:570-579.
    PubMed     Abstract available


    August 2022
  52. BREE KK, Hensley PJ, Lobo N, Brooks NA, et al
    All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guerin Response in High-Grade Ta Tumors.
    J Urol. 2022;208:284-291.
    PubMed     Abstract available


  53. HAKIMI K, Carbonara U, Djaladat H, Mehrazin R, et al
    Outcomes of Lymph Node Dissection in Nephroureterectomy in the Treatment of Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry.
    J Urol. 2022;208:268-276.
    PubMed     Abstract available


    July 2022
  54. MCELREE IM, Steinberg RL, Martin AC, Richards J, et al
    Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guerin-Naive High-Risk Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2022 Jul 27:101097JU0000000000002740. doi: 10.1097/JU.0000000000002740.
    PubMed     Abstract available


  55. MCELREE IM, Packiam VT, Steinberg RL, Mott SL, et al
    Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment OF NON-MUSCLE Invasive Bladder Cancer.
    J Urol. 2022 Jul 5:101097JU0000000000002848. doi: 10.1097/JU.0000000000002848.
    PubMed     Abstract available


  56. SONG Y, Du Y, Qin C, Bai F, et al
    Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. Letter.
    J Urol. 2022;208:222-223.
    PubMed    


    June 2022
  57. GESSNER KH, Siemens DR, Bjurlin MA
    Re: Does Smoking Cessation Reduce Bladder Cancer Recurrence?
    J Urol. 2022 Jun 21:101097JU0000000000002832. doi: 10.1097/JU.0000000000002832.
    PubMed    


  58. ROSEN GH, Nallani A, Muzzey C, Murray KS, et al
    Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
    J Urol. 2022;207:1302-1311.
    PubMed     Abstract available


    May 2022
  59. STOVER AM, Basak R, Mueller D, Lipman R, et al
    Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2022 May 31:101097JU0000000000002747. doi: 10.1097/JU.0000000000002747.
    PubMed     Abstract available


  60. KATES M, Mansour AM, Lamm DL, Shore N, et al
    Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Non-muscle Invasive Bladder Cancer.
    J Urol. 2022 May 16:101097JU0000000000002778. doi: 10.1097/JU.0000000000002778.
    PubMed     Abstract available


  61. HUELSTER HL, Sexton WJ
    Real-World Outcomes Driving the Needle toward Simplification of Nonmuscle Invasive Bladder Cancer Risk Stratification.
    J Urol. 2022 May 2:101097JU0000000000002731. doi: 10.1097/JU.0000000000002731.
    PubMed    



  62. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer.
    J Urol. 2022;207:1166.
    PubMed    


  63. MASTROIANNI R, Ferriero M, Tuderti G, Anceschi U, et al
    Open Radical Cystectomy versus Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Early Outcomes of a Single-Center Randomized Controlled Trial.
    J Urol. 2022;207:982-992.
    PubMed     Abstract available


    April 2022
  64. SONG Y, Du Y, Qin C, Xu T, et al
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis. Letter.
    J Urol. 2022;207:937.
    PubMed    


  65. YANAGISAWA T, Mori K, Motlagh RS, Kawada T, et al
    En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology.
    J Urol. 2022;207:754-768.
    PubMed     Abstract available


  66. MATIN SF, Pierorazio PM, Kleinmann N, Gore JL, et al
    Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
    J Urol. 2022;207:779-788.
    PubMed     Abstract available


  67. RICHTER LA, Osazuwa-Peters OL, Routh JC, Handa VL, et al
    Vaginal Complications after Cystectomy: Results from a Medicare Sample.
    J Urol. 2022;207:789-796.
    PubMed     Abstract available


    March 2022
  68. GESSNER KH, Siemens DR, Bjurlin MA
    Does Smoking Cessation Reduce Bladder Cancer Recurrence?
    J Urol. 2022 Mar 15:101097JU0000000000002649. doi: 10.1097/JU.0000000000002649.
    PubMed    


    February 2022
  69. MITRA AP, Cai J, Miranda G, Bhanvadia S, et al
    Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases.
    J Urol. 2022;207:302-313.
    PubMed     Abstract available


  70. MIEST T, Khanna A, Sharma V, Hensley PJ, et al
    Development and Validation of a Risk-Adapted Scoring Model for Metachronous Upper Tract Urothelial Carcinoma following Radical Cystectomy.
    J Urol. 2022;207:284-292.
    PubMed     Abstract available


    January 2022
  71. FURBERG H, Petruzella S, Whiting K, Stein E, et al
    Association of Biochemically Verified Post-diagnosis Smoking and Non-muscle Invasive Bladder Cancer Recurrence Risk.
    J Urol. 2022 Jan 27:101097JU0000000000002449. doi: 10.1097/JU.0000000000002449.
    PubMed     Abstract available


  72. MONAGHAN TF, Wagg AS, Rahman SN, Winer AG, et al
    Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy. Letter.
    J Urol. 2022;207:237-238.
    PubMed    


  73. CHESNUT GT, Goh AC
    Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy. Reply.
    J Urol. 2022;207:238-239.
    PubMed    


  74. GOLD SA, Kenigsberg AP, Lotan Y
    Diagnostic and Cost Implications of the 2020 AUA Microhematuria Guidelines: Modeling Impact in a Large Public Health Care System.
    J Urol. 2022;207:52-60.
    PubMed     Abstract available


    December 2021
  75. RIVEROS C, Jazayeri SB, Chalfant V, Ahmed F, et al
    The Geriatric Nutritional Risk Index Predicts Postoperative Outcomes in Bladder Cancer: A Propensity Score-Matched Analysis.
    J Urol. 2021 Dec 2:101097JU0000000000002342. doi: 10.1097/JU.0000000000002342.
    PubMed     Abstract available


  76. KHALEEL S, Regmi S, Hannah P, Watarai B, et al
    Impact of Preoperative Immunonutrition on Perioperative Outcomes Following Cystectomy. Reply.
    J Urol. 2021;206:1531-1532.
    PubMed    


  77. ALSYOUF M, Djaladat H
    Impact of Preoperative Immunonutrition on Perioperative Outcomes following Cystectomy. Letter.
    J Urol. 2021;206:1530-1531.
    PubMed    


  78. RAMAN JD, Kavalieris L, Konety B, Porten S, et al
    The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma.
    J Urol. 2021;206:1380-1389.
    PubMed     Abstract available


  79. YANKELEVICH GR, Dreher PC, Taylor Z, Kim D, et al
    Socio-Environmental Conditions Associated with Geospatial Clusters of Urothelial Carcinoma: A Multi-Institutional Analysis.
    J Urol. 2021;206:1390-1402.
    PubMed     Abstract available


    November 2021
  80. MICHAEL J, Matulewicz RS, Bjurlin MA
    Assessment of Tobacco Screening and Smoking Cessation Recommendations Among Bladder Cancer Guidelines: A Call to Action.
    J Urol. 2021 Nov 30:101097JU0000000000002360. doi: 10.1097/JU.0000000000002360.
    PubMed    


  81. OEFELEIN MG
    The Continued Importance of Transurethral Resection of Bladder Tumor (TURBT) in the Treatment of Bladder Cancer.
    J Urol. 2021 Nov 5:101097JU0000000000002325. doi: 10.1097/JU.0000000000002325.
    PubMed    


  82. KHALEEL S, Regmi S, Hannah P, Watarai B, et al
    Impact of Preoperative Immunonutrition on Perioperative Outcomes following Cystectomy.
    J Urol. 2021;206:1132-1138.
    PubMed     Abstract available


  83. HENSLEY PJ, Bree KK, Campbell MT, Alhalabi O, et al
    Progression of Disease after Bacillus Calmette-Guerin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
    J Urol. 2021;206:1258-1267.
    PubMed     Abstract available


  84. SCHUETTFORT VM, Pradere B, D'Andrea D, Grossmann NC, et al
    Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy.
    J Urol. 2021;206:1122-1131.
    PubMed     Abstract available


    October 2021
  85. CHAPPIDI MR, Yang H, Meng MV, Bivalacqua TJ, et al
    Utility of Blue Light Cystoscopy for Post-BCG Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons.
    J Urol. 2021 Oct 25:101097JU0000000000002308. doi: 10.1097/JU.0000000000002308.
    PubMed     Abstract available


  86. BREE KK, Navai N
    Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Reply.
    J Urol. 2021 Oct 25:101097JU0000000000002307. doi: 10.1097/JU.0000000000002307.
    PubMed    


  87. DE LA CALLE CM, Patel SH, Kates M
    Contemporary Rates of Gynecologic Organ Involvement in Females With Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Letter.
    J Urol. 2021 Oct 25:101097JU0000000000002306. doi: 10.1097/JU.0000000000002306.
    PubMed    


  88. KHANNA A, Miest T, Sharma V, Campbell R, et al
    Role of Lymphadenectomy During Radical Cystectomy for Non-muscle Invasive Bladder Cancer: Results From a Multi-Institutional Experience.
    J Urol. 2021 Oct 25:101097JU0000000000002266. doi: 10.1097/JU.0000000000002266.
    PubMed     Abstract available


  89. LOTAN Y, de Jong J, Liu VYT, Bismar TA, et al
    Patients With Muscle Invasive Bladder Cancer with Non-luminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.
    J Urol. 2021 Oct 13:101097JU0000000000002261. doi: 10.1097/JU.0000000000002261.
    PubMed     Abstract available


  90. GHOREIFI A, Douglawi A, Djaladat H
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-analysis. Letter.
    J Urol. 2021;206:1071.
    PubMed    


  91. SHARMA V, Miest TS, Chamie K, Matin SF, et al
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-analysis. Reply.
    J Urol. 2021;206:1072.
    PubMed    


  92. KHANNA A, Zganjar A, Lyon T, Shah P, et al
    A Contemporary Analysis of Urethral Recurrence following Radical Cystectomy.
    J Urol. 2021;206:970-977.
    PubMed     Abstract available


    September 2021
  93. CARY C, Tong Y, Linsell S, Ghani K, et al
    Ranking Important Factors for Using Postoperative Chemotherapy in Non-Muscle Invasive Bladder Cancer: Conjoint Analysis Results From the Michigan Urological Surgery Improvement Collaborative (MUSIC).
    J Urol. 2021 Sep 23:101097JU0000000000002233. doi: 10.1097/JU.0000000000002233.
    PubMed     Abstract available


  94. WETTSTEIN MS, Baxter NN, Sutradhar R, Mamdani M, et al
    Factors Associated with Re-resection in T1 Bladder Cancer: Identifying Patients Who do Not Receive Guideline-Concordant Care at the Population Level.
    J Urol. 2021 Sep 22:101097JU0000000000002229. doi: 10.1097/JU.0000000000002229.
    PubMed     Abstract available


  95. MONTORSI F, Moschini M, Necchi A, Deho F, et al
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guerin. Letter.
    J Urol. 2021 Sep 14:101097JU0000000000002237. doi: 10.1097/JU.0000000000002237.
    PubMed    


  96. HENSLEY PJ, Kamat AM
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guerin. Response.
    J Urol. 2021 Sep 14:101097JU0000000000002238. doi: 10.1097/JU.0000000000002238.
    PubMed    


  97. HENSLEY PJ, Kamat AM
    Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: Implications for Clinical Trial Design. Reply.
    J Urol. 2021 Sep 2:101097JU0000000000002238. doi: 10.1097/JU.0000000000002238.
    PubMed    


  98. SHARMA V, Miest TS, Juvet TS, Toussi A, et al
    The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis.
    J Urol. 2021;206:558-567.
    PubMed     Abstract available


  99. PETROS FG, Choi W, Qi Y, Moss T, et al
    Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.
    J Urol. 2021;206:548-557.
    PubMed     Abstract available


  100. KATIMS AB, Say R, Derweesh I, Uzzo R, et al
    Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration).
    J Urol. 2021;206:568-576.
    PubMed     Abstract available


    August 2021
  101. D'ANDREA D, Black PC, Zargar H, Dinney CP, et al
    Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle-Invasive Bladder Cancer.
    J Urol. 2021 Aug 27:101097JU0000000000002190. doi: 10.1097/JU.0000000000002190.
    PubMed     Abstract available


  102. PATEL HD, Patel SH, Blanco-Martinez E, Kuzbel J, et al
    Four versus Three Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathologic Response and Survival.
    J Urol. 2021 Aug 27:101097JU0000000000002189. doi: 10.1097/JU.0000000000002189.
    PubMed     Abstract available


  103. CHEVLI KK, Shore ND, Trainer A, Smith AB, et al
    Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Using UGN-102, A Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
    J Urol. 2021 Aug 26:101097JU0000000000002186. doi: 10.1097/JU.0000000000002186.
    PubMed     Abstract available


  104. MERSEBURGER AS, Castellano D, Powles T, Loriot Y, et al
    Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
    J Urol. 2021;206:240-251.
    PubMed     Abstract available


  105. PATEL SR, Lerner SP
    Novel Thermo-Sensitive Hydrogel Therapy for Low-Grade Upper Tract Urothelial Carcinoma.
    J Urol. 2021;206:191-193.
    PubMed    


    July 2021
  106. SCHOENBERG M, Steinberg G
    Rethinking the Treatment of Recurrent Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2021;206:7-9.
    PubMed    


  107. PIERETTI A, Krasnow R, Drumm M, Gusev A, et al
    Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy.
    J Urol. 2021;206:29-36.
    PubMed     Abstract available


    June 2021
  108. ZHANG R, Zang J, Xie F, Zhang Y, et al
    Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
    J Urol. 2021 Jun 1:101097JU0000000000001878. doi: 10.1097/JU.0000000000001878.
    PubMed     Abstract available


    May 2021
  109. CHAKIRYAN NH, Jiang DD, Gillis KA, Green E, et al
    Pathologic Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    J Urol. 2021 May 25:101097JU0000000000001855. doi: 10.1097/JU.0000000000001855.
    PubMed     Abstract available


  110. MARTINI A, Afferi L, Zamboni S, Schultz JG, et al
    Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy.
    J Urol. 2021 May 25:101097JU0000000000001886. doi: 10.1097/JU.0000000000001886.
    PubMed     Abstract available


  111. WOLDU SL, Ng CK, Loo RK, Slezak JM, et al
    Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.
    J Urol. 2021;205:1387-1393.
    PubMed     Abstract available


  112. HASHEM A, Abol-Enein H, Laymon M, Abdellutif MM, et al
    A Randomized Trial to Examine the Utility of Mebeverine on the Early Return of Continence Following Orthotopic Bladder Substitution.
    J Urol. 2021;205:1400-1406.
    PubMed     Abstract available


  113. MATULEWICZ RS, Basak R, Zambrano I, Dearing BA, et al
    Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
    J Urol. 2021;205:1444-1451.
    PubMed     Abstract available


  114. WYMER KM, Sharma V, Saigal CS, Chamie K, et al
    Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guerin-Unresponsive Carcinoma In Situ of the Bladder.
    J Urol. 2021;205:1326-1335.
    PubMed     Abstract available


    April 2021
  115. BREE KK, Hensley PJ, Westerman MB, Kokorovic A, et al
    Contemporary Rates of Gynecologic Organ Involvement in Females With Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy Following Neoadjuvant Chemotherapy.
    J Urol. 2021 Apr 19:101097JU0000000000001784. doi: 10.1097/JU.0000000000001784.
    PubMed     Abstract available


  116. BAUSCH K, Halbeisen FS, Aghlmandi S, Sutter SU, et al
    Reply by Authors.
    J Urol. 2021;205:998.
    PubMed    


  117. SOUNTOULIDES P, Pyrgidis N, Brookman-May S, Mykoniatis I, et al
    Does Ureteral Stenting Increase the Risk of Metachronous Upper Tract Urothelial Carcinoma in Patients with Bladder Tumors? A Systematic Review and Meta-analysis.
    J Urol. 2021;205:956-966.
    PubMed     Abstract available


  118. SHVERO A, Abu-Ghanem Y, Laufer M, Dotan ZA, et al
    Endoscopic Treatment for Large Multifocal Upper Tract Urothelial Carcinoma.
    J Urol. 2021;205:1039-1046.
    PubMed     Abstract available


    March 2021
  119. LUSTY A, Doiron RC, Booth CM, Whitehead M, et al
    No Outcome Differences after Cystectomy Between Patients with de Novo Muscle-Invasive Bladder Cancer Compared to Progressors: A Retrospective Population-Based Study.
    J Urol. 2021 Mar 30:101097JU0000000000001715. doi: 10.1097/JU.0000000000001715.
    PubMed     Abstract available


  120. YANAGISAWA T, Miki J, Sakanaka K, Fukuokaya W, et al
    Clinical Significance of Horizontal and Vertical Margin of En Bloc Resection for Non-Muscle Invasive Bladder Cancer.
    J Urol. 2021 Mar 29:101097JU0000000000001735. doi: 10.1097/JU.0000000000001735.
    PubMed     Abstract available



  121. Erratum: Perceptions of Link between Smoking and Bladder Cancer among United States Adults.
    J Urol. 2021;205:942.
    PubMed    



  122. Erratum: Microbiome of Catheter Collected Urine in Males with Bladder Cancer According to Disease Stage.
    J Urol. 2021;205:942.
    PubMed    


  123. DAS A, Cohen JE, Ko OS, Jordan BJ, et al
    Surgeon Scorecards Improve Muscle Sampling on Transurethral Resection of Bladder Tumor and Recurrence Outcomes in Patients with Nonmuscle Invasive Bladder Cancer.
    J Urol. 2021;205:693-700.
    PubMed     Abstract available


  124. TAGUCHI S, Tambo M, Watanabe M, Machida H, et al
    Prospective Validation of Vesical Imaging-Reporting and Data System Using a Next-Generation Magnetic Resonance Imaging Scanner-Is Denoising Deep Learning Reconstruction Useful?
    J Urol. 2021;205:686-692.
    PubMed     Abstract available


  125. SWAMI U, Haaland B, Kessel A, Nussenzveig R, et al
    Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
    J Urol. 2021;205:709-717.
    PubMed     Abstract available


    February 2021
  126. BHAT A, Kwon D, Soodana-Prakash N, Mouzannar A, et al
    Surveillance Intensity in Intermediate Risk Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy.
    J Urol. 2021 Feb 22:101097JU0000000000001689. doi: 10.1097/JU.0000000000001689.
    PubMed     Abstract available


  127. ZHU D, Srivastava A, Agalliu I, Fram E, et al
    Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population.
    J Urol. 2021 Feb 22:101097JU0000000000001694. doi: 10.1097/JU.0000000000001694.
    PubMed     Abstract available


  128. MICHELLE R, Liguori G, Trombetta C
    Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis. Letter.
    J Urol. 2021 Feb 12:101097JU0000000000001649. doi: 10.1097/JU.0000000000001649.
    PubMed    


  129. ZIBELMAN M, Asghar AM, Parker DC, O'Neill J, et al
    Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial.
    J Urol. 2021 Feb 4:101097JU0000000000001602. doi: 10.1097/JU.0000000000001602.
    PubMed     Abstract available


  130. FURRER MA, Kiss B, Studer UE, Wuethrich PY, et al
    Seminal Vesical Sparing Cystectomy in Bladder Cancer Patients is Feasible with Good Functional Results without Impairing Oncological Outcomes: A Longitudinal Long-Term Propensity-Matched Single Center Study.
    J Urol. 2021 Feb 3:101097JU0000000000001635. doi: 10.1097/JU.0000000000001635.
    PubMed     Abstract available


  131. GHOREIFI A, Djaladat H
    Re: Intra-Operative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication RatesDonat SM, Tan KS, Jibara G, Dalbagni G, Arslan Carlon V, Sandhu J J Urol 2020; doi:10.1097/JU.0000000000001329.
    J Urol. 2021;205:335-336.
    PubMed    


  132. DONAT SM, Tan KS, Jibara G, Dalbagni G, et al
    Intraoperative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication Rates.
    J Urol. 2021;205:483-490.
    PubMed     Abstract available


  133. CACCIAMANI GE, Medina L, Lin-Brande M, Tafuri A, et al
    Timing, Patterns and Predictors of 90-Day Readmission Rate after Robotic Radical Cystectomy.
    J Urol. 2021;205:491-499.
    PubMed     Abstract available


  134. ELSAYED AS, Gibson S, Jing Z, Wijburg C, et al
    Rates and Patterns of Recurrences and Survival Outcomes after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Urol. 2021;205:407-413.
    PubMed     Abstract available


  135. GALLIOLI A, Territo A, Mercade A, Fontana M, et al
    The Impact of Ureteroscopy following Computerized Tomography Urography in the Management of Upper Tract Urothelial Carcinoma.
    J Urol. 2021;205:392-399.
    PubMed     Abstract available


  136. WEI XX, Werner L, Teo MY, Rosenberg JE, et al
    Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
    J Urol. 2021;205:414-419.
    PubMed     Abstract available


  137. CHESNUT GT, Tin AL, Sjoberg DD, Jang B, et al
    Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy.
    J Urol. 2021;205:400-406.
    PubMed     Abstract available


    January 2021
  138. MATULAY JT, Li R, Hensley PJ, Brooks NA, et al
    Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design.
    J Urol. 2021 Jan 27:101097JU0000000000001633. doi: 10.1097/JU.0000000000001633.
    PubMed     Abstract available


  139. YANAGISAWA T, Miki J, Yorozu T, Iwatani K, et al
    Vertical Lamina Propria Invasion Diagnosed by En Bloc Transurethral Resection is a Significant Predictor of Progression for pT1 Bladder Cancer.
    J Urol. 2021 Jan 27:101097JU0000000000001630. doi: 10.1097/JU.0000000000001630.
    PubMed     Abstract available


  140. WEIN AJ
    Voiding Function and Dysfunction, Bladder Physiology and Pharmacology, and Female Urology.
    J Urol. 2021;205:309-312.
    PubMed    


  141. MEEKS JJ
    Editorial Comment.
    J Urol. 2021;205:107.
    PubMed    


  142. HATAKEYAMA S, Hamano I, Ohyama C
    Editorial Comment.
    J Urol. 2021;205:107.
    PubMed    


  143. HAUTMANN RE, Volkmer B, Egghart G, Frohneberg D, et al
    Functional Outcome and Complications following Ileal Neobladder Reconstruction in Male Patients without Tumor Recurrence. More than 35 Years of Experience from a Single Center.
    J Urol. 2021;205:174-182.
    PubMed     Abstract available


    December 2020
  144. PETRUZELLA S, Bochner BH, Kenney J, Whiting K, et al
    Examining the Accuracy of Self-Reported Smoking-Related Exposure Among Recently Diagnosed Non-muscle Invasive Bladder Cancer Patients.
    J Urol. 2020 Dec 24:101097JU0000000000001571. doi: 10.1097/JU.0000000000001571.
    PubMed     Abstract available


  145. KIRSCHNER AN, Wang J, Rajkumar-Calkins A, Neuzil KE, et al
    Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model.
    J Urol. 2020 Dec 24:101097JU0000000000001576. doi: 10.1097/JU.0000000000001576.
    PubMed     Abstract available


  146. BAUSCH K, Halbeisen FS, Aghlmandi S, Sutter SU, et al
    Antimicrobial Prophylaxis for Postoperative Urinary Tract Infections in Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis.
    J Urol. 2020 Dec 7:101097JU0000000000001513. doi: 10.1097/JU.0000000000001513.
    PubMed     Abstract available


  147. CHANG SS
    Re: Impact of Adjuvant Chemotherapy in Patients with Adverse Features and Variant Histology at Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder: Does Histologic Subtype Matter?
    J Urol. 2020;204:1378.
    PubMed    


  148. MORI K, Abufaraj M, Mostafaei H, Quhal F, et al
    A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy.
    J Urol. 2020;204:1129-1140.
    PubMed     Abstract available


    November 2020
  149. DE JONG FC, Hoedemaeker RF, Kvikstad V, Mensink JTM, et al
    T1-Substaging of Non-muscle Invasive Bladder Cancer is Associated with BCG-Failure and Improves Patient Stratification at Diagnosis.
    J Urol. 2020 Nov 16:101097JU0000000000001422. doi: 10.1097/JU.0000000000001422.
    PubMed     Abstract available


  150. YIN G, Tang J, Wang L
    Re: A Urine Based Genomic Assay to Triage Patients with Hematuria for CystoscopyK. E. M. van Kessel, J. J. de Jong, A. C. J. Ziel-van der Made, H. Roshani, S. M. Haensel, J. H. Wolterbeek, E. R. Boeve, E. H. G. M. Oomens, N. J. van Casteren, M. Krispi
    J Urol. 2020;204:1062.
    PubMed    


  151. HANNA PT, Peterson M, Albersheim J, Drawz P, et al
    Acute Kidney Injury following Enhanced Recovery after Surgery in Patients Undergoing Radical Cystectomy.
    J Urol. 2020;204:982-988.
    PubMed     Abstract available


  152. WANG DS
    Re: Epidural Anesthesia is Associated with Increased Complications in Cystectomy Patients: A NSQIP Analysis.
    J Urol. 2020;204:1072-1073.
    PubMed    


    October 2020
  153. MYRIE AK, Matulewicz RS
    Perceptions of the Link Between Smoking and Bladder Cancer Among United States Adults.
    J Urol. 2020 Oct 14:101097JU0000000000001415. doi: 10.1097/JU.0000000000001415.
    PubMed    


  154. SCHMIDT A, Warmann SW, Eckert F, Ellerkamp V, et al
    The Role of Reconstructive Surgery and Brachytherapy in Pediatric Bladder/Prostate Rhabdomyosarcoma.
    J Urol. 2020;204:825-834.
    PubMed     Abstract available


  155. ALMASSI N, Cha EK, Vertosick EA, Huang C, et al
    Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience.
    J Urol. 2020;204:677-684.
    PubMed     Abstract available


  156. CACCIAMANI GE, Ghodoussipour S, Mari A, Gill KS, et al
    Association between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes following Radical Cystectomy: Systematic Review and Meta-Analysis.
    J Urol. 2020;204:649-660.
    PubMed     Abstract available


    September 2020
  157. LAVIANA AA, Stone BV, Avulova S
    Editorial Comment.
    J Urol. 2020;204:458-459.
    PubMed    


  158. KRETSCHMER A
    Editorial Comment.
    J Urol. 2020;204:458.
    PubMed    


  159. CHANG SS
    Editorial Comment.
    J Urol. 2020;204:449.
    PubMed    


  160. CADEDDU JA
    Re: Long-Term Oncological Outcomes from an Early Phase Randomised Controlled Three-Arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    J Urol. 2020;204:598.
    PubMed    


  161. DASON S, Cha EK, Falavolti C, Vertosick EA, et al
    Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations.
    J Urol. 2020;204:460-465.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.